Overview

Synchron is the leading endovascular BCI company, pursuing neural recording without traditional open-brain surgery. Founded in 2016 by Australian neurologist Tom Oxley, the company has raised $345 million total, including a $200 million Series D round in November 2025, reaching an estimated $1 billion valuation.

Technical Approach

Synchron’s Stentrode is a stent-mounted electrode array delivered via catheter through the patient’s vascular system to the motor cortex region. This approach eliminates the need for open cranial surgery, reducing infection risk and recovery time. The electrodes record neural activity from the superior sagittal sinus, a major brain vein, achieving adequate signal quality for motor control.

Backing and Partnerships

The company is backed by major philanthropies including the Bill and Melinda Gates Foundation and the Bezos Earth Fund. Strategic partnerships with Apple and NVIDIA signal integration toward consumer-friendly interfaces. These relationships demonstrate confidence in the endovascular approach and suggest pathways to commercial deployment beyond clinical settings.

Clinical Progress

Synchron has demonstrated functional motor control in human patients, with participants achieving cursor and robotic limb manipulation through neural signals. The endovascular methodology positions the company as a lower-risk alternative to penetrating electrode approaches.